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Today, there is good evidence that neonatal respir-
atory distress syndrome (RDS) can be prevented,
to some extent, and be treated by instilling surfac-
tant into the trachea, thus replacing what the
preterm neonate is seriously missing. Before dis-
cussing the most recent experiences, however, al-
low me to go back in time and look at some of
the events that lead up to the situation of today.
The surfactant story starts with VON NEERGAARD
who was far ahead of his time and whose publica-
tion of 1929, as a result, was met with very little
understanding and interest [18]. By replacing all
the air in the lungs of an animal with a liquid,
VON NEERGAARD described how he could turn
back the clock and return the lungs to the situa-
tion they were in when the animal had just been
born, and had not yet taken its first breath. Ex-
panding the air-free lungs with a liquid, VON NEER-
GAARD found, required considerably less pressure
than expanding them with air. He drew the conclu-
sion that, when air was the expanding medium,
the added resistance was due to surface tension in
the many air liquid interfaces of the airways. That
was basically VON NEERGAARD'S contribution.
When nobody responded to his publication, not
in Switzerland where he lived nor anywhere else
in the world, he left the subject for good.
Almost twenty years later, PETER GRUENWALD [14]
rediscovered the importance of surface tension as
something resisting the first breath of an infant.
GRUENWALD'S experiments were similar to those
of VON NEERGAARD. He found that expanding the
lungs of a preterm stillborn infant with air re-
quired more pressure than expanding the lungs
with saline, but the pressure required for aeration
was reduced if a surface active agent was added
to the liquid in the airways. That clearly demon-
strated that surface tension was resisting aeration;
the more surface tension was lowered with the
surface-active agent, the easier was the aeration.
The lungs of an infant dying shortly after birth,
who never got the lungs expanded, will often show
that the air had moved down through the wider
airways, but was stopped when the airways be-
came narrower. Air moving into a liquid-filled
tube is resisted by surface tension and that resist-
ance is greater the narrower the tube. A well-
known method of determining surface tension of
a liquid is to measure the height to which a liquid
rises in a narrow glass tube (figure 1). Suppose
we use that method and enclose the lower end of
the glass tube. The enclosed space has been given
the shape of a thorax. If pressure is lowered in
this "thorax" by the "diaphragm" moving down,
the meniscus can be pulled down to the level of
the surrounding liquid. The force required to hold
the meniscus at that level, where gravity is of no
consequence, is the pressure difference across the
meniscus, ΔΡ, times the cross section of the tube,
πΚ2, R being the radius of the tube lumen. That
force is counteracted by surface tension of the
airway liquid, γ, acting along the inner circumfer-
ence of the tube, 2πΚ. We, thus, get
ΔΡ · πΚ2 = γ - 2πΚ,
from which we delete π and an R on each side
of the equal sign and end up with the simple
equation,
ΔΡ = 2y/R,
the Law of Laplace. This law tells us that the
resistance to the first breath, which is due to
surface tension, is directly in proportion to γ,
surface tension of the airway fluid, and inversely
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Figure 1. Liquid in narrow glass capillary rises because
of surface tension (left). If the lower end of the capillary
is enclosed and pressure is reduced so that the air-liquid
interface comes down to the level of the surrounding
liquid (center), the pressure difference, ΔΡ, is counterac-
ting surface tension only. The Law of Laplace, ΔΡ =
2y/R, can then be derived (see text). If the volume is
reduced further and is oscillating (right), pressure
around the bubble can be recorded. The bubble is not
pulsating between vertical arrows but maintained at
maximal size. The mark at the peaks of the tracing
indicates minimal bubble size.
related to the airway radius, R. When GRUEN-
WALD lowered the value of γ by adding a surface-
active agent, he reduced resistance to aeration,
and the air-liquid interfaces could move more
readily through the finer terminal airways.
Suppose we lower pressure further. We then over-
come the effect of gravity and the meniscus moves
down to the lower end of the tube. Then, as a
bubble suddenly expands, ΔΡ is instantaneously
reduced, obvisouly because the radius has en-
larged. Suppose we were to make the bubble
"breathe" by moving the diaphragm up and down.
A dilemma would then became obvious; the trans-
mural pressure required to keep a small bubble
expanded would be greater than that needed for
a large bubble. In the lung, the situation is just
the opposite. PATTLE in England was the first
person who helped clarify this dilemma [19]. He
found that bubbles squeezed from the cut surface
of the lung could be very small; yet, the gas inside
the bubbles, which ought to be under high pres-
sure, was not quickly absorbed by the surrounding
liquid. Instead, the bubbles could be observed
through a microscope for a long time. PATTLE
concluded that the lung must produce a substance
that forms a film in the bubble's air-liquid inter-
face, lowering surface tension to very low values,
so that pressure inside the bubble is hardly higher
than outside and yet the radius is small.
Using the modified Wilhelmy balance, CLEMENTS
clarified PATTLE'S experiments [2]. He found the
substance produced by the lung would lower sur-
face tension to close to zero, and when the film
was expanded again, surface tension would in-
crease to about 40 mN/m. Clements concluded
that this changing surface tension would stabilize
the lung and prevent the alveolus from collapsing
when it was diminishing in size during expiration.
When the main component of surfactant, dipalmi-
toyl phosphatidylcholine (DPPC), was studied
with this instrument, the tracing obtained was
similar to that of pulmonary surfactant; very low
surface tension was obtained with film compres-
sion. For this reason, it was not surprising that,
when it had been reported by AVERY and MEAD
that infants dying from RDS had a surfactant
deficiency, attempts were made to treat the condi-
tion by replacing the missing surfactant, using
only the main component, DPPC. This was done
by a team in Canada [20], and by CHU et al. [3],
from San Francisco, who went to Singapore to
carry out their clinical trial. The results of these
two studies were not encouraging. DPPC alone
did not seem to cure RDS.
At that time, my collaborators and I had devel-
oped another method for studying the surface
properties of pulmonary surfactant: the pulsating
bubble surfactometer [1, 4]. Its principle is to
measure pressure around a bubble expanded in
the liquid to be evaluated. The bubble, like an
alveolus, communicates with ambient air and is
made to pulsate while the pressure is recorded
(figure 1). When the sample consists of natural
surfactant, obtained from a saline la vage of adult
animals' airways, a monomolecular film will
quickly form. When the bubble is approaching
minimal size and the surface film molecules are
forced to come closer together, however, the pres-
sure difference across the bubble surface, ΔΡ, is
almost zero. When the bubble is coming to its
maximal size, ΔΡ is about 1.5 cm water. With
the Law of Laplace, it can be calculated that, at
minimal size, surface tension is close to zero. At
maximal size, when the bubble has a radius of
0.55 mm, surface tension is 30 — 35 mN/m, thus
in fair agreement with values found with the Wil-
helmy balance. On the other hand, DPPC, when
J. Perinat. Med. 15(1987)
Enhorning, Surfactant supplementation 481
studied alone in suspension, requires a very long
time to form a monolayer at the bubble's surface.
When DPPC was studied with the Wilhelmy bal-
ance, it had been dissolved in hexane and the
solution had been spread over the water in the
trough. When the hexane had evaporated, the film
was ready for study. That was very different from
the way the film can be expected to form in the
lung of a neonate. In other words, we found
with the pulsating bubble surfactometer, that the
adsorption rate for DPPC alone was far too low;
whereas, a film would form almost instan-
taneously with natural surfactant. This made us
believe that the principle of surfactant replace-
ment was sound and we were encouraged to carry
out a number of animal experiments [5, 7, 8]. They
proved to us that the preterm neonate, who is at
great risk of developing RDS, with surfactant
supplementation prior to the first breath, will have
a facilitated and even expansion of the lung. This,
in turn, resulted in increased survival rate.
We then tried the principle of surfactant supple-
mentation prior to the first breath with a series
of experiments on Rhesus monkies [6]. Six of the
primate neonates were delivered at approximately
130 days and treated with surfactant. An addi-
tional six were delivered at the same gestational
age and served as controls. The monkey neonates
were treated as intensely as human premature
neonates would be, i.e., the respiratory support
was altered depending on the results of frequent
blood gas analysis. We found that FiCh could be
clearly lowered in the treated animals. Yet, their
hypoxia was less and their survival was improved.
The monkey experiments were certainly encourag-
ing, but we were not ready for a clinical trial since
the surfactant preparation we had used had a high
protein content (~ 10%) and was not sterile. Any
attempt to sterilize resulted in loss of surface activ-
ity. We found, however, that the lipids that could
be extracted from natural surfactant, after reex-
traction and acetone precipitation had a protein
content of less than 1%, and formed an active
preparation when resuspended in an electrolyte
solution. That preparation tolerated sterilization
by autoclaving. We were then ready for a clinical
trial, but we were not to be the first. As much as
four years had elapsed since FUJIWARA et al. [11]
reported their successful surfactant treatment of
infants with severe RDS.
Our aim was to prevent, and not to treat, RDS
by supplying surfactant before it was needed. If
deposited in high concentrations in the upper air-
ways before the first breath, the surfactant would
be acting, from the very beginning, right where it
was needed, at the air-liquid interface. It would
lower resistance to the first breath and automati-
cally be evenly distributed. A monolayer film
would be left outlining the alveoli and, most im-
portantly, the cylindrical airways. With early ad-
ministration, prior to the first breath, damage to
the airway epithelium should be possible to avoid
since respirator pressures could be lower and the
need for extra oxygen would be less. The surfac-
tant preparation we used was prepared from the
lipids that could be extracted from a calf lung
lavage.
We restricted our study [9] to infants born at a
gestational age of less than 30 weeks. Those born
27 — 29 weeks received 4ml surfactant, i.e., 100
mg phospholipids, and those born before 27 weeks
received 3ml, i.e., 75 mg phospholipids. Each
infant was intubated immediately after birth and
the first breath was inhibited until surfactant, or
air for the controls, had been deposited through
the tracheal tube. Following two or three manual
inflations with a bag, the infant was connected to
a respirator, the setting of which was guided by
the results of the blood gas analysis. The study
that was randomized went on for a year. It showed
that, of the 39 infants who had received surfactant,
only 1 died neonatally; whereas, of the 33 controls,
six died.
The infants receiving surfactant clearly benefited:
They required less oxygen and their ventilation
index, the peak inspiratory pressure times fre-
quency, could be kept lower. Our experiences are
in accord with those of others using a preparation
from calf lung lavage [15, 21], with those using
human surfactant [16,17], and with those adminis-
tering surfactant TA [10, 11, 13] the preparation
originally described by FUJIWARA et al. [12]. The
total picture is clear: surfactant instillation will
help prevent or quickly alleviate RDS.
Summary
Pulmonary surfactant is a complex mixture, but clearly
has one main component, dipalmitoylphosphatidylcho-
line, or DPPC. The respiratory distress syndrome, RDS,
a condition afflicting the baby born too early, is caused
by a deficiency of pulmonary surfactant. When this was
first realized, attempts were made to treat the condition
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by supplying DPPC, the main component of the missing
surfactant. These first attempts to supplement the pul-
monary surfactant were unsuccessful, however, and with
the bubble surfactometer, it is clearly seen that DPPC
alone does not have the needed surface properties. The
adsorption rate is too low, i. e., DPPC only is very slow
in forming a film at the air-liquid interface. Natural
surfactant on the other hand has the capacity to form
a film instantaneously. Therefore, if natural surfactant
is supplied in the upper airways prior to the first breath,
Keywords: Bubble Surfactometer, dipalmitoylphosphatidylcholine (DPPC), respiratory distress syndrome (RDS),
surfactant supplementation.
it will immediately upgrade the maturity of the neonate's
lungs; aeration is facilitated and the lungs are given
stability.
With a surfactant preparation, consisting of the lipids
extracted from calf lung lavage, a randomized clinical
trial was carried out on infants at particularly high
risk of developing RDS. Of the 39 infants receiving
surfactant prior to the first breath after birth, only one
died neonatally; whereas, of the 33 controls, six died.
Zusammenfassung
Der Surfactant kann zugeführt werden, bevor das Neuge-
borene ihn benötigt
Der Lungensurfactant ist eine komplexe Mischung, hat
aber eine Hauptkomponente, das Dipalmitoylphospha-
tidylcholin oder DPPC. Dem Atemnotsyndrom oder
RDS als Komplikation des Frühgeborenen liegt ein
Mangel an Surfactant zugrunde. Nachdem dies bekannt
war, versuchte man, ein RDS mit DPPC zu behandeln.
Es ließen sich keine Erfolge erzielen und mit dem
Schaum-Surfactometer läßt sich nachweisen, daß DPPC
allein nicht die geforderten Oberflächeneigenschaften
besitzt. Die Adsorption erfolgt zu langsam oder anders
ausgedrückt, DPPC bildet nur sehr langsam einen Film
an der Grenzschicht zwischen Luft und Flüssigkeit. Ein
natürlicher Surfactant kann dagegen sofort einen sol-
chen Film herstellen. Wird vor dem ersten Atemzug
natürlicher Surfactant in die oberen Luftwege gegeben,
kann sofort die Lungenreife beeinflußt werden; die Be-
lüftung und die Stabilität der Lungen werden verbessert.
Mit einer speziellen Surfactantlösung, die extrahierte
Lipide aus Lavagen von Kalbslungen enthielt, wurde
eine randomisierte klinische Studie bei Kindern mit ho-
hem Risiko für die Entwicklung eines RDS durchge-
führt. Von den 39 Kindern, die den Surfactant vor dem
ersten postnatalen Atemzug erhielten, starb nur eines,
während von den 33 Kontrollkindern sechs starben.
Schlüsselwörter: Dipalmitoylphosphatidylcholin (DPPC), RDS, Schaum-Surfactometer, Surfactantersatz.
Resume
L'apport de surfactant peut etre effectue avant que le
nouveau-ne le necessite
Le surfactant pulmonaire est un melange complexe, mais
ä Pevidence il possede un composant principal, le dipal-
mitoylphosphatidylcholine ou DPPC. Le syndrome de
detresse respiratoire, SDR, pathologie touchant le
nouveau-ne ne trop tot, est provoque par un deficit en
surfactant pulmonaire. Lorsqu'on realisa cela pour la
premiere fois, des essais ont etc entrepris pour traiter
cette pathologie en ajoutant le DPPC, le composant
principal du surfactant manquant. Ces premieres tentati-
ves pour ajouter du surfactant pulmonaire furent infruc-
tueuses, neanmoins, a Paide du surfactometre a bulle, il
apparait clairement que le DPPC tout seul n'a pas les
proprietes de surface recherchees. Le taux d'absorption
est trop faible, c'est-a-dire que le DPPC seul est trop
lent pour etablir un film a l'interface airliquide. Le
surfactant naturel, ä l'inverse, a la capacite de former
un film instantanement. C'est ainsi que si on apporte
du surfactant naturel dans les voies aeriennes superieures
avant la premiere respiration, il ameliorera immediate-
ment la maturite des poumons du nouveau-ne; Paeration
est facilitee et les poumons acquierent une stabilite.
A Paide d'une preparation de surfactant, com'prenant
des lipides extraits de lavages pulmonaires de veaux, un
essai clinique randomise a ete realise chez des enfants
hautement a risque de developper un SDR. Sur les
39 enfants ayant recu du surfactant avant la premiere
respiration apres la naissance un seul est decode en
periode neonatale; tandis que six sont morts sur les 33
temoins.
Mots-cles: Apport de surfactant, dipalmitoylphosphadidylcholine (DPPC), surfactometre a bulle, syndrome de
detresse respiratoire (SDR).
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